| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15a46cf9d6723a32997302b46dae5d4c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-26 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N59-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 |
| filingDate |
2016-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a409687de81121fd10b47ed6252e9e59 |
| publicationDate |
2022-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11224633-B2 |
| titleOfInvention |
Kit for treating sepsis and/or any systemic (SIRS) or damaging cellular hyperinflammation |
| abstract |
Disclosed is a kit including a first container including a composition including at least one antioxidant selenoprotein and at least one second container including at least one composition including at least one oxidant selenocompound. Also disclosed is a method of administration that allows to administer effective and cytotoxic doses of selenocompounds, allowing the inhibition of the hyper-activation of phagocytes and in particular of circulating immature neutrophils and directly and indirectly protects endothelial cells, in particular for the treatment of sepsis, SIRS and leukemia. Further disclosed is an administration device adapted to the administration method. |
| priorityDate |
2015-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |